BPMC stock forecast
Our latest prediction for Blueprint Medicines Corp.'s stock price was made on the June 12, 2019 when the stock price was at 86.19$.
In the short term (2weeks), BPMC's stock price should outperform the market by 0.07%. During that period the price should oscillate between -8.00% and +8.70%.
In the medium term (3months), BPMC's stock price should outperform the market by 0.15%. During that period the price should oscillate between -17.48% and +24.54%.Get email alerts
About Blueprint Medicines Corp.
Blueprint Medicines Corp. is a precision therapy company. It focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.
At the moment the company generates 16M USD in revenues.
On its last earning announcement, the company reported a loss of -7.76$ per share.
The book value per share is 12.60$
Three months stock forecastJune 12, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|